Company news
Lyell Immunopharma, Inc. news in 2022
Lyell Immunopharma, Inc.'s news releases, calls and decks from 2022, newest first.
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
December 14, 2022
Lyell Immunopharma to Participate in BofA Securities Biotech Conference
November 30, 2022
Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
November 9, 2022
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
November 7, 2022
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
November 6, 2022
Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference
November 1, 2022
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
October 5, 2022
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 4, 2022
Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer
September 27, 2022
Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022
September 11, 2022
Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference
August 29, 2022
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
August 3, 2022
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference
June 6, 2022
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
May 9, 2022
Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting
May 1, 2022
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
March 28, 2022
Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting
March 7, 2022
Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer
January 30, 2022
Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK
January 23, 2022
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022